This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on Web of Science (16)  • Contact me when this article is cited  Related Content  • Related letter  • Similar articles in JAMA  Social Bookmarking   What's this?

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor: In their Research Letter, Dr Green and colleagues¹ reported 3 cases of myelosuppression with red cell hypoplasia that occurred during linezolid therapy. We report here a case of reversible sideroblastic anemia that appeared within 2 months of linezolid treatment.

A 61-year-old man with chronic leg osteomyelitis due to Staphylococcus aureus, Enterococcus faecalis, and Morganella morganii was treated by debridement surgery and antibiotics including linezolid (600 mg twice daily) and ofloxacin (400 mg twice daily) for 60 days. He was also receiving ranitidine. During this period, platelet and leukocyte counts remained stable while hemoglobin concentration progressively decreased from 15.4 to 7.8 g/dL. Anemia was microcytic (mean corpuscular volume 83 fL), with a reticulocyte count of 28 x 10³/µL. Vitamin B12, folate, and ferritin serum levels were normal. Serum iron was increased at 219 µg/dL (normal, <175 µg/dL) and transferrin level was reduced at 150 mg/dL . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED LETTER

Linezolid and Reversible Myelosuppression
Stephen L. Green, John C. Maddox, and Eric D. Huttenbach
JAMA. 2001;285(10):1291.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Safety, efficacy and pharmacokinetics of linezolid for treatment of resistant Gram-positive infections in cancer patients with neutropenia
Smith et al.
Ann Oncol 2003;14:795-801.
ABSTRACT | FULL TEXT